Results of Mitotech’s Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
Dec 27, 2015
Mitotech published the results of its Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome Advances in Therapy journal. This open access publication can be found here:
http://link.springer.com/article/10.1007/s12325-015-0273-6/fulltext.html
About Mitotech S.A
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed antioxidants. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.
News & Events
- Mitotech Completes First Patient Visit in VISTA-1 - Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
- Mitotech Initiates Phase 3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology
- Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease
- Mitotech announces new Dry Eye data set supporting SkQ1’s novel mechanism of action
- Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients
- Mitotech’s SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication
- Mitotech’s lead compound significantly increased lifespan of rapidly aging mice